Uncategorized
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
Merck is planning a pivotal trial for Winrevair in an uncommon kind of heart failure after seeing a “pretty profound” benefit at the lowest dose used in a Phase 2 test, Chief Medical Officer Eliav … Read More